{"title":"Unusual complications after MammoSite brachytherapy: out‐of‐field rib fracture and Mondor's disease","authors":"E. Rahimy, S. Evans","doi":"10.1002/pro6.1128","DOIUrl":null,"url":null,"abstract":"Recent reports have documented in‐field rib fractures as a rare complication of accelerated partial breast irradiation. Here, we report a case of an out‐of‐field rib fracture, with a maximum point dose of <50% of the prescribed dose, and Mondor's disease in a 61‐year‐old woman after MammoSite brachytherapy. This is the first case in the literature in which rib fractures occurred out‐of‐field, without trauma or risk factors. It also highlights a rare clinical entity, Mondor's disease, of which its recognition is important for radiation oncologists given its potential for tumor recurrence.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pro6.1128","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pro6.1128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Recent reports have documented in‐field rib fractures as a rare complication of accelerated partial breast irradiation. Here, we report a case of an out‐of‐field rib fracture, with a maximum point dose of <50% of the prescribed dose, and Mondor's disease in a 61‐year‐old woman after MammoSite brachytherapy. This is the first case in the literature in which rib fractures occurred out‐of‐field, without trauma or risk factors. It also highlights a rare clinical entity, Mondor's disease, of which its recognition is important for radiation oncologists given its potential for tumor recurrence.